[go: up one dir, main page]

AU5597500A - Streptavidin expressed gene fusions and methods of use thereof - Google Patents

Streptavidin expressed gene fusions and methods of use thereof

Info

Publication number
AU5597500A
AU5597500A AU55975/00A AU5597500A AU5597500A AU 5597500 A AU5597500 A AU 5597500A AU 55975/00 A AU55975/00 A AU 55975/00A AU 5597500 A AU5597500 A AU 5597500A AU 5597500 A AU5597500 A AU 5597500A
Authority
AU
Australia
Prior art keywords
methods
expressed gene
gene fusions
streptavidin
streptavidin expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55975/00A
Inventor
Stephen Charles Goshorn
Scott Stoll Graves
Yukang Lin
John M. Reno
James Allen Sanderson
Joanne Elaine Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of AU5597500A publication Critical patent/AU5597500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU55975/00A 1999-06-07 2000-06-05 Streptavidin expressed gene fusions and methods of use thereof Abandoned AU5597500A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13790099P 1999-06-07 1999-06-07
US60137900 1999-06-07
US16897699P 1999-12-03 1999-12-03
US60168976 1999-12-03
PCT/US2000/015595 WO2000075333A1 (en) 1999-06-07 2000-06-05 Streptavidin expressed gene fusions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU5597500A true AU5597500A (en) 2000-12-28

Family

ID=26835691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55975/00A Abandoned AU5597500A (en) 1999-06-07 2000-06-05 Streptavidin expressed gene fusions and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1190061A1 (en)
JP (1) JP2003501096A (en)
AU (1) AU5597500A (en)
CA (1) CA2376192A1 (en)
WO (1) WO2000075333A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047620A2 (en) * 2001-12-07 2003-06-12 Virexx Research, Inc. Compositions and methods for producing vascular occlusion
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20100069815A1 (en) 2006-06-27 2010-03-18 Asahi Kasei Kabushiki Kaisha Substrate for biological fluid treatment
NZ585465A (en) * 2007-11-12 2012-12-21 Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
WO2010095455A1 (en) * 2009-02-20 2010-08-26 国立大学法人 東京大学 Hypo-immunogenic streptavidin and use thereof
MX2011011825A (en) 2009-05-11 2011-12-06 U3 Pharma Gmbh Humanized axl antibodies.
DE102009047243A1 (en) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospecific Polypeptide Reagents
WO2021262872A2 (en) * 2020-06-24 2021-12-30 Repertoire Immune Medicines, Inc. Mhc multimer expression constructs and uses thereof
WO2022087154A1 (en) * 2020-10-20 2022-04-28 Repertoire Immune Medicines, Inc. Mhc class ii peptide multimers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583940D1 (en) * 1984-10-02 1991-10-02 Harry M Meade PRODUCTION OF STREPTAVIDINE-LIKE POLYPEPTIDES.
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
CA2136178A1 (en) * 1992-05-29 1993-12-09 Vasantha Nagarajan Production of streptavidin from bacillus subtilis
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
WO1995015770A1 (en) * 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
EP0861325A1 (en) * 1995-11-16 1998-09-02 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods

Also Published As

Publication number Publication date
WO2000075333A9 (en) 2002-06-20
JP2003501096A (en) 2003-01-14
EP1190061A1 (en) 2002-03-27
CA2376192A1 (en) 2000-12-14
WO2000075333A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2468401A (en) Underreamer and method of use
AU4055600A (en) Impaction substrate and methods of use
AU6340600A (en) Telomerase inhibitors and methods of their use
AU2002353095A1 (en) Streptavidin expressed gene fusions and methods of use thereof
AU6117000A (en) Novel polynucleotides and method of use thereof
AU4657500A (en) Locked nucleic acid hybrids and methods of use
AU6037199A (en) Rac-like genes from maize and methods of use
AU6746800A (en) Carbon-reinforced electrode and method of making same
AU1047901A (en) Methods of genetic cluster analysis and use thereof
AU7616300A (en) Refractory nzp-type structures and method of making and using same
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2309700A (en) Oligonucleotide array and methods of use
AU2839401A (en) Enzymes and genes used for producing vanillin
AU2002246808A1 (en) Human nucleic acids and polypeptides and methods of use thereof
AU5886500A (en) Indolyl-benzimidazole antibacterials, and methods of use thereof
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU5597500A (en) Streptavidin expressed gene fusions and methods of use thereof
AU3553400A (en) Use and production of polypropylene
AU6094200A (en) Nor gene compositions and methods for use thereof
AU1955201A (en) Insecticide targets and methods of use
AU4708200A (en) Tow and process of making
AU2400401A (en) Novel phosphodiesterases and genes thereof
AU1894601A (en) Novel gene and use thereof
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase